C9169 HCPCS Level II code: Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

CMS terminated C9169: its last date of service was Dec 31, 2024. It stays here for looking up older claims; newer services need a current code.

Official description

C9169

Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

Short description: Inj, nogapendekin pmln 1 mcg

HCPCS · United States

Medicare details

The indicators CMS publishes with C9169 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
Statute
Type of service
Medical care
BETOS category
Other drugs
Coverage statute
1833(t)
Added
Oct 1, 2024
Terminated after
Dec 31, 2024

Where C9169 sits

  1. 1C codesOutpatient prospective payment system
  2. 2Terminated C9169Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

Is HCPCS code C9169 still valid?

No. CMS terminated C9169; its last date of service was Dec 31, 2024. It is listed for looking up services from before then. Use a current code for newer services.

Does Medicare cover C9169?

CMS lists C9169’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.